A
Alloplex Biotherapeutics
Dedicated to exploring the higher order combinatorial space of immunomodulators to develop an effective anti-tumor vaccine
About Alloplex Biotherapeutics
Alloplex Biotherapeutics operates in the biotechnology sector, focusing on developing innovative cellular therapies for cancer treatment. The company's core product is the SUPLEXA therapeutic cells, which are reprogrammed rather than genetically engineered to recognize and kill tumor cells. This approach allows for a simple, inexpensive, and reproducible manufacturing process that does not require genetic engineering or feeder cells, making it GMP (Good Manufacturing Practice) compatible. Alloplex serves the oncology market, targeting various types of tumors with its tumor-agnostic platform. The business model revolves around research and development, clinical trials, and eventual commercialization of its cellular therapies. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of its therapeutic products once they receive regulatory approval.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2023 | $25M | $100M | Undisclosed | ↗ |
| EARLY VCEquity / VC | Aug 2021 | $1M | $4M | Daewoong Pharmaceutical | — |
Growth signals
Latest recorded traffic for Alloplex Biotherapeutics is 1.1K monthly website visits, down 15.4% over the last three months. Alloplex Biotherapeutics's team grew 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Alloplex Biotherapeutics in the Boston ecosystem
The Alloplex Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Daewoong Pharmaceutical
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alloplex Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alloplex Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









